ArticleFrontiers in cellular and infection microbiology2017
Combination of Erythromycin and Curcumin Alleviates
Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 41 citations in OpenAlex.
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Evaluation of hydrogel loading with curcumin and silver nanoparticles: biocompatibilities and anti-biofilm activities.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Article
- The Role of mRNA Modifications in Bone Diseases.International journal of biological sciences · 2025Review
- The Application of Rat Models inPathogens (Basel, Switzerland) · 2024Review
- Exploring the potential of naturally occurring antimicrobials for managing orthopedic-device-related infections.Journal of bone and joint infection · 2024Review
- Natural medicine delivery from 3D printed bone substitutes.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- The Natural Product Curcumin as an Antibacterial Agent: Current Achievements and Problems.Antioxidants (Basel, Switzerland) · 2022Review
- Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.Frontiers in cellular and infection microbiology · 2022Article
- The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice.Antibiotics (Basel, Switzerland) · 2021Article
- Effects of Curcumin and Its Analogues on Infectious Diseases.Advances in experimental medicine and biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteomyelitis is commonly caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.